You are here

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

Submitted by admin on August 3, 2018 - 11:04am

Source:

CP Wire

News Tags:

Summit Therapeutics

microbiome ridinilazole

Headline:

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial

snippet:

Ridinilazole treatment resulted in a 59% reduction in recurrence compared to vancomycin
C. difficile causes approximately 500,000 infections and 29,000 deaths in the US annually
There are at least 12 products in development that target the microbiome in treating C. difficile